Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

SAN DIEGO, Nov. 7, 2013 /PRNewswire/ -- Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced third quarter and year-to-date operating results for 2013.  The company will host a conference call today to discuss financial results for the third quarter and year-to-date, and to provide an operational update on developments in the quarter.

"We are pleased to have made good progress toward our goals during the third quarter, moving forward in the development of our lead drug candidate, quizartinib.  We are excited about the upcoming events at ASH in December, where we will have the opportunity to present data from our most recent studies," said Michael Martino, Ambit's president and Chief Executive Officer. "As we head into the last quarter of 2013, we are looking forward to feedback from our upcoming FDA meeting in November and we will provide an update on our development and regulatory plans for quizartinib following that meeting.  Additionally, we remain on track to start our Phase 3 trial in early-2014, as previously guided."

Operational Update
The Company is pleased to announce the acceptance of four abstracts with preliminary data highlighting the Company's lead drug candidate, quizartinib.  Presentations of the final data and two additional posters will be presented during the ASH 55th Annual Meeting at the Ernest Morial Convention Center in New Orleans, LA on December 9, 2013.  Oral presentations include the following:

Results of Phase 2 Randomized, Open-Label, Study of Lower Doses of Quizartinib in Subjects with FLT3-ITD Positive Relapsed Acute Myeloid Leukemia (AML):  The purpo
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
(Date:1/15/2014)... Two champions of science, technology, engineering, and ... annual competition for middle and high school students designed ... study. The competition presents students with real-world problems experienced ... Mathematics, and Sciences is a program administered by ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
(Date:1/14/2014)... Jan. 14, 2014  3D Communications, a leading provider of strategic communications ... and media events in the United States ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2
... BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today ... will host a,conference call and webcast on Tuesday, ... discuss first quarter 2008 financial results., ... International Dial-in Number: 617.597.5308 Participant Code: ...
... Amsterdam,Molecular Therapeutics (Euronext: AMT), a leader in the ... of the newly created Next Biotech Index of,NYSE Euronext. ... company,for this index," said Ronald Lorijn, CEO of AMT. ... and will help investors to track,the performance of our ...
... and Patient Report,Transfer Across Disparate PACS and Maintains Hospital Group,s ... ... RIS Crashes, SEATTLE, April 8, 2008 Compressus, ... of an integrated digital imaging and data management,solution at E-Rad ...
Cached Biology Technology:BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET) 2Amsterdam Molecular Therapeutics Part of Next Biotech Index 2Compressus Completes Interoperability Implementation for E-Rad Solutions Teleradiology Customers 2Compressus Completes Interoperability Implementation for E-Rad Solutions Teleradiology Customers 3
(Date:4/17/2014)... our ideas about domestication derive from Charles Darwin, ... British animal-breeding practices during the 19th century, a ... , It is from Darwin that we ... captive animals from wild species and total human ... animal management in this industrial setting has been ...
(Date:4/16/2014)... University researchers have identified a new syndrome called "osteosarcopenic ... muscle mass with obesity. , "It used to be ... your bones would be because the bones were supporting ... of Nutrition at Florida State. "But, that,s only true ...
(Date:4/16/2014)... Professor Nicolas Doucet of the Centre INRSInstitut Armand-Frappier has just ... (NIH) in the amount of nearly US$600,000. The 5-year grant ... proteins called RNases and to explore their biomedical potential in ... asthma. , "Receiving a grant at this level ...
Breaking Biology News(10 mins):The story of animal domestication retold 2The story of animal domestication retold 3The story of animal domestication retold 4Researchers: Obesity can amplify bone and muscle loss 2High-level NIH grant goes to professor Nicolas Doucet of INRS 2
... have so far been starch and cane sugar. In ... University study was to use only lignocellulose, otherwise known ... production. Another new breakthrough in the ... biotechnology. Finland,s advanced forest industry provides particularly good opportunities ...
... In an example of life imitating art, biologists ... living neon sign composed of millions of bacterial cells ... Their achievement, detailed in this week,s advance online issue ... fluorescent protein to the biological clocks of the bacteria, ...
... that could revolutionize biomedical research, scientists have discovered a way ... from an individual cancer patient alive in the laboratory ... in the lab after dividing only a few times, and ... body. This new technique, described today online in the ...
Cached Biology News:Chemicals and biofuel from wood biomass 2Researchers create living 'neon signs' composed of millions of glowing bacteria 2Researchers create living 'neon signs' composed of millions of glowing bacteria 3Georgetown researchers lead discovery expected to significantly change biomedical research 2
Mouse monoclonal antibody raised against a partial recombinant DENR. NCBI Entrez Gene ID = DENR...
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
... I can be used in intracellular staining ... cells and to serve as an antibody ... cell permeabilization is a reversible process, it ... the presence of saponin during intracellular staining. ...
Mouse monoclonal antibody raised against a full length recombinant GPT. NCBI Entrez Gene ID = GPT...
Biology Products: